Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 19, 2017
What is the competitive landscape for ALPHARMA, and when can generic versions of ALPHARMA drugs launch?
ALPHARMA has sixty-three approved drugs.| International Patents: | 48 |
| US Patents: | 9 |
| Tradenames: | 45 |
| Ingredients: | 42 |
| NDAs: | 63 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
morphine sulfate and naltrexone hydrochloride | Extended-release Capsules | 30 mg/1.2 mg, 50 mg/2 mg and 80 mg/3.2 mg | EMBEDA | 5/28/2010 |
morphine sulfate and naltrexone hydrochloride | Extended-release Capsules | 60 mg/2.4 mg | EMBEDA | 5/25/2010 |
morphine sulfate and naltrexone hydrochloride | Extended-release Capsules | 100 mg/4 mg | EMBEDA | 5/3/2010 |
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| European Patent Office | 2224806 | ► Subscribe | |||||||||||||
| Japan | 2009541320 | ► Subscribe | |||||||||||||
| Spain | 2600141 | ► Subscribe | |||||||||||||
| Australia | 2013257508 | ► Subscribe | |||||||||||||
| Slovenia | EP2526932 | ► Subscribe | |||||||||||||
| Poland | 2484346 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 2009079518 | ► Subscribe | |||||||||||||
| Slovenia | EP2484346 | ► Subscribe | |||||||||||||
| Portugal | 2484346 | ► Subscribe | |||||||||||||
| Russian Federation | 2009101082 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/GB98/013 | United Kingdom | ► Subscribe | PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923 | ||||||||||||
| C/GB12/058 | United Kingdom | ► Subscribe | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 | ||||||||||||
| C0012 | France | ► Subscribe | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 | ||||||||||||
| C/GB10/012 | United Kingdom | ► Subscribe | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 | ||||||||||||
| C0038 | France | ► Subscribe | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,947 others who get our Drug Patent Expiration Alerts:
